Switch theme
Sign up to access all valuation multiples
Abbott India Ltd is a drug manufacturing company that offers products in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. Its patient focus centers overwhelmingly on women's health and gastrointestine, gastroenterology, and hepatic care. Geographically, the majority of the company's revenue is generated in India.
1944
3.8K+
LTM Revenue $755M
LTM EBITDA $203M
$7.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abbott India has a last 12-month revenue (LTM) of $755M and a last 12-month EBITDA of $203M.
In the most recent fiscal year, Abbott India achieved revenue of $751M and an EBITDA of $231M.
Abbott India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abbott India valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $755M | XXX | $751M | XXX | XXX | XXX |
| Gross Profit | $338M | XXX | $341M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $203M | XXX | $231M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $205M | XXX | $190M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $169M | XXX | $166M | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Abbott India's stock price is INR 30453 (or $357).
Abbott India has current market cap of INR 647B (or $7.6B), and EV of INR 615B (or $7.2B).
See Abbott India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.2B | $7.6B | XXX | XXX | XXX | XXX | $7.93 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Abbott India has market cap of $7.6B and EV of $7.2B.
Abbott India's trades at 9.8x EV/Revenue multiple, and 32.3x EV/EBITDA.
Equity research analysts estimate Abbott India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abbott India has a P/E ratio of 44.9x.
See valuation multiples for Abbott India and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.6B | XXX | $7.6B | XXX | XXX | XXX |
| EV (current) | $7.2B | XXX | $7.2B | XXX | XXX | XXX |
| EV/Revenue | 9.5x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | 35.6x | XXX | 32.3x | XXX | XXX | XXX |
| EV/EBIT | 35.2x | XXX | 39.2x | XXX | XXX | XXX |
| EV/Gross Profit | 21.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 44.9x | XXX | 47.5x | XXX | XXX | XXX |
| EV/FCF | 120.3x | XXX | 60.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbbott India's last 12 month revenue growth is 8%
Abbott India's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $40K for the same period.
Abbott India's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abbott India's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abbott India and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $40K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abbott India acquired XXX companies to date.
Last acquisition by Abbott India was XXXXXXXX, XXXXX XXXXX XXXXXX . Abbott India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abbott India founded? | Abbott India was founded in 1944. |
| Where is Abbott India headquartered? | Abbott India is headquartered in India. |
| How many employees does Abbott India have? | As of today, Abbott India has 3.8K+ employees. |
| Is Abbott India publicy listed? | Yes, Abbott India is a public company listed on BOM. |
| What is the stock symbol of Abbott India? | Abbott India trades under 500488 ticker. |
| When did Abbott India go public? | Abbott India went public in 1992. |
| Who are competitors of Abbott India? | Similar companies to Abbott India include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Abbott India? | Abbott India's current market cap is $7.6B |
| What is the current revenue of Abbott India? | Abbott India's last 12 months revenue is $755M. |
| What is the current revenue growth of Abbott India? | Abbott India revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Abbott India? | Current revenue multiple of Abbott India is 9.5x. |
| Is Abbott India profitable? | Yes, Abbott India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Abbott India? | Abbott India's last 12 months EBITDA is $203M. |
| What is Abbott India's EBITDA margin? | Abbott India's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Abbott India? | Current EBITDA multiple of Abbott India is 35.6x. |
| What is the current FCF of Abbott India? | Abbott India's last 12 months FCF is $59.9M. |
| What is Abbott India's FCF margin? | Abbott India's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Abbott India? | Current FCF multiple of Abbott India is 120.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
